共 50 条
- [1] Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE StudyJOURNAL OF CROHNS & COLITIS, 2021, 15 (07): : 1120 - 1129Sandborn, William J.Feagan, Brian G.Hanauer, StephenVermeire, SeverineGhosh, SubrataLiu, Wenzhong J.Petersen, AnnKatrinCharles, LornaHuang, VivianUsiskin, KeithWolf, Douglas C.D'Haens, Geert
- [2] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSIONGASTROENTEROLOGY, 2023, 164 (06) : S208 - S208Abreu, Maria T.Danese, SilvioWolf, Douglas C.Canavan, James B.Jain, AnjaliWu, HsiuanlinPetersen, AnnKatrinCharles, LornaAfzali, AnitaPanaccione, Remo
- [3] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extensionJOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534Panaccione, R.Danese, S.Wolf, D. C.Canavan, J. B.Jain, A.Wu, H.Petersen, A.Charles, L.Afzali, A.Abreu, M. T.
- [4] Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label ExtensionJOURNAL OF CROHNS & COLITIS, 2024, 18 (02): : 264 - 274Danese, SilvioPanaccione, RemoAbreu, Maria T.Rubin, David T.Ghosh, SubrataDignass, AxelAfzali, AnitaWolf, Douglas C.Chiorean, Michael, VVermeire, SeverineJain, AnjaliCharles, LornaLawlor, GarrettOsterman, Mark T.Wu, HsiuanlinCanavan, James B.Petersen, AnnkatrinColombel, Jean-FredericRegueiro, Miguel
- [5] EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDYGASTROENTEROLOGY, 2022, 162 (07) : S965 - S965Panaccione, RemoAfzali, AnitaHudesman, DavidLawlor, GarrettOsterman, Mark T.Eren, DevrimMemaj, ArteidRegueiro, Miguel D.Ghosh, Subrata
- [6] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extensionJOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101Siegel, C.Danese, S.Rubin, D. T.Sabino, J.Long, M. D.Cross, R. K.Armuzzi, A.Blumenstein, I.Kobayashi, T.Lama, S.Charles, L.Cetin, V.Petersen, A.Wu, H.Wang, D.Jain, A.D'Haens, G.
- [7] Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label ExtensionAMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1063 - S1063Abraham, Bincy P.Longman, RandyKatsanos, KonstantinosLee, Scott D.Kobayashi, TakuBettenworth, DominikKorman, LouisMehra, DimpySantiago, Norma RuizPetersen, AnnkatrinDesai, ManikWu, HsiuanlinWang, DongOsterman, Mark T.Jain, AnjaliTorres, Joana
- [8] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosisEUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324Selmaj, K. W.Ziemssen, T.Comi, G.Hartung, H. P.Singal, M.Thorpe, A.Riolo, J. V.Cheng, C. Y.Sheffield, J. K.Krakovich, A.Vermersch, P.Cree, B. A. C.
- [9] RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDYGASTROENTEROLOGY, 2022, 162 (07) : S229 - S229Afzali, AnitaChiorean, Michael V.Lawlor, GarrettOsterman, Mark T.Eren, DevrimMemaj, ArteidPanaccione, RemoGhosh, Subrata
- [10] Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension studyJOURNAL OF CROHNS & COLITIS, 2025, 19 : i104 - i106Atreya, R.Louis, E.Loftus Jr., E., VRubin, D. T.Dubinsky, M.Hisamatsu, T.Kalabic, J.Mendez, P.Chen, S.Shah, S.Morisset, P.Duan, W. R.Panaccione, R.